Results 161 to 170 of about 134,363 (333)
ESC Heart Failure, Volume 12, Issue 2, Page 1416-1426, April 2025.Abstract Aims SPARCL1 was recently identified as a biomarker of right ventricular (RV) maladaptation in patients with pulmonary hypertension (PH), and N‐terminal pro‐brain natriuretic protein (NT‐proBNP) is an established biomarker of RV failure in PH. The present study investigated whether NT‐proBNP and SPARCL1 concentrations are associated with load ...
Oliver Dörr +15 more
wiley +1 more source
The Use of B-type Natriuretic Peptide (BNP) to Distinguish Heart Failure from Lung Disease in Patients Presenting with Dyspnea to the Emergency Department [PDF]
, 2003 Gene R. Pesola
openalex +1 more source
ESC Heart Failure, Volume 12, Issue 4, Page 2608-2620, August 2025.Abstract Right ventricular failure (RVF) is a common complication following left ventricular assist device (LVAD) implantation and increases patient morbidity and mortality. Due to the complex and limited understanding of RVF pathophysiology, efforts to prognosticate RVF after LVAD have been challenging.
Abdul‐Fatawu Osman +11 more
wiley +1 more source
Qual o valor do BNP na prática clínica em pacientes com insuficiência cardíaca? [PDF]
, 2003 Fábio Fernandes, Charles Mady
openalex +1 more source
Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang +3 more
wiley +1 more source
ESC Heart Failure, Volume 12, Issue 2, Page 1427-1436, April 2025.Abstract Background and objectives Initially described as a benign acute cardiomyopathy, Takotsubo syndrome has been linked to elevated mortality rates. Emerging evidence suggests that unresolved myocardial inflammation may contribute to this adverse prognosis.
Loïc Faucher +12 more
wiley +1 more source
BNP level as a useful predictive marker for LV remodeling after AMI [PDF]
, 2003 Byung‐Su Yoo +5 more
openalex +1 more source
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
ESC Heart Failure, Volume 12, Issue 2, Page 1437-1446, April 2025.• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
547 Cardiac resynchronisation therapy in refractory heart failure: relation of LV diastolic function to BNP levels [PDF]
, 2003 Giuseppina Belotti +2 more
openalex +1 more source